Skip to content

Sarepta Bolstered by Doctor Letter Urging FDA Approval of DMD Drug

March 21, 2016

Thirty-six doctors, all experts in Duchenne muscular dystrophy, or DMD, have written a letter to the U.S. Food and Drug Administration urging the agency to approve Sarepta Therapeutics’ (SRPTGet Report) experimental therapy eteplirsen.

The lobbying effort seeking to bolster support for eteplirsen and Sarepta — and counter previously released FDA criticism of the drug — is ramping up as an advisory committee meeting on April 25 nears.Click here to read more.